MTOR and cancer: The abnormal expression and activation of AXL provides cancer cells a survival advantage by activating the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) and MAPK pro-survival pathways as well as pathways related to cell growth, migration, and invasion [16].